Jefferies Downgrades ResMed (RMD) to Underperform; AirSense10 Cycle Waning

August 23, 2016 6:58 AM EDT
Get Alerts RMD Hot Sheet
Price: $63.72 --0%

Rating Summary:
    6 Buy, 8 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 27 | New: 31
Trade RMD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies downgraded ResMed (NYSE: RMD) from Hold to Underperform with a price target of $58.00 (from $60.00), saying the AirSense10 Cycle is waning.

Analyst Anthony Petrone commented, "We conducted a DME survey and several expert calls to gauge the latest CPAP trends. AirSense10 is still considered best-in-class, but Dream has closed the gap while being priced at a discount. Lower Medicare rates effective July 1, 2016 are pressuring private rates and are expected to lead to further DME consolidation and price pressure. Downgrading to UP as cycles evolve."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $69.78 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Jefferies & Co

Add Your Comment